Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-13-000031
Filing Date
2013-11-14
Accepted
2013-11-14 16:07:33
Documents
11
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20130930x10q.htm 10-Q 909950
8 EX-31.1 c617-20130930ex31100a9f9.htm EX-31.1 15786
9 EX-31.2 c617-20130930ex3129913d2.htm EX-31.2 16100
10 EX-32.1 c617-20130930ex321a5967f.htm EX-32.1 14069
11 GRAPHIC c617-20130930x10qg1.jpg GRAPHIC 18865
  Complete submission text file 0000926617-13-000031.txt   2724241

Data Files

Seq Description Document Type Size
2 EX-101.CAL c617-20130930_cal.xml EX-101.CAL 32936
3 EX-101.DEF c617-20130930_def.xml EX-101.DEF 50406
4 EX-101.INS c617-20130930.xml EX-101.INS 214589
5 EX-101.LAB c617-20130930_lab.xml EX-101.LAB 168553
6 EX-101.PRE c617-20130930_pre.xml EX-101.PRE 134934
7 EX-101.SCH c617-20130930.xsd EX-101.SCH 21263
Mailing Address 12117 BEE CAVES ROAD BUILDING TWO SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING TWO SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 131219928
SIC: 2835 In Vitro & In Vivo Diagnostic Substances